首页|舒血宁联合依达拉奉对急性脑梗死患者神经功能和血管再通的影响分析

舒血宁联合依达拉奉对急性脑梗死患者神经功能和血管再通的影响分析

扫码查看
目的:探讨急性脑梗死患者应用舒血宁联合依达拉奉治疗的临床效果及对神经功能、血管再通的影响。方法:选取寿光市中医医院2021年 1月—2024年 1月收治的 90例急性脑梗死患者为研究对象,按随机数表法将患者分为对照组和研究组,各45例。对照组应用依达拉奉治疗,研究组在对照组基础上联合舒血宁治疗,比较两组临床治疗总有效率、神经功能、生活自理能力、血管再通情况及不良反应发生情况。结果:研究组临床治疗总有效率为93。33%,高于对照组的73。33%,差异有统计学意义(P<0。05)。治疗后,研究组美国国立卫生研究院卒中量表评分为(8。77±0。72)分,低于对照组的(10。44±0。58)分,日常生活活动能力量表评分为(75。08±4。11)分,高于对照组的(67。25±4。08)分,差异均有统计学意义(P<0。05)。研究组血管再通率为95。56%,高于对照组的73。33%,差异有统计学意义(P<0。05)。研究组头晕头痛、身体浮肿、皮肤瘙痒、食欲降低等不良反应发生率为 20。00%,低于对照组的 24。44%,但两组比较差异无统计学意义(P>0。05)。结论:急性脑梗死患者应用舒血宁联合与依达拉奉进行治疗的临床效果确切,能够改善神经功能,促使血管再通,提高生活质量,安全性良好。
Effect Analysis of Shuxuening Combined with Edaravone on Nerve Function and Vascular Recanalization in Patients with Acute Cerebral Infarction
Objective:To investigate the clinical effect of Shuxuening combined with Edaravone on nerve function and vascular recanalization in patients with acute cerebral infarction.Methods:A total of 90 patients with acute cerebral infarction admitted to Shouguang Hospital of Traditional Chinese Medicine from January 2021 to January 2024 were selected as the study objects and divided into a control group and a study group according to random number table method,with 45 cases in each group.The control group was treated with Edaravone,and the study group was combined with Shuxuening on the basis of the control group.The total effective rate,nerve function,self-care ability,vascular recanalization and adverse reactions of the two groups were observed and compared.Results:The total effective rate of the study group was 93.33%,which was higher than 73.33%of the control group,the difference was statistically significant(P<0.05).After treatment,the National Institutes of Health Stroke Scale score of the study group was(8.77±0.72)points,which was lower than(10.44±0.58)points of the control group,and the Activity of Daily Living scale score was(75.08±4.11)points,which was higher than(67.25±4.08)points of the control group,the differences were statistically significant(P<0.05).The vascular revascularization rate in the study group was 95.56%,which was higher than 73.33%in the control group,the difference was statistically significant(P<0.05).The incidence of dizziness,headache,edema,pruritus and decreased appetite in the study group was 20.00%,which was lower than 24.44%in the control group,but the difference was not statistically significant between the two groups(P>0.05).Conclusion:The clinical effect of Shuxuening combined with Edaravone in the treatment of acute cerebral infarction patients is accurate,which can improve nerve function,promote vascular recanalization,improve quality of life,and have good safety.

Acute cerebral infarctionShuxueningEdaravoneNeurological functionVascular recanalizationAdverse reactions

张丽敏、马彦梅

展开 >

山东省寿光市中医医院脑病二科,山东 寿光 262700

山东省寿光市中医医院脑病一科,山东 寿光 262700

急性脑梗死 舒血宁 依达拉奉 神经功能 血管再通 不良反应

2024

中国伤残医学
中国康复医学会,黑龙江省截瘫研究所

中国伤残医学

影响因子:0.451
ISSN:1673-6567
年,卷(期):2024.32(13)